Huons Global Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 09:57 pm EST
Share
Huons Global Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 1,313.55 million compared to KRW 1,896.22 million a year ago. Net income was KRW 11,063.11 million compared to KRW 5,963.33 million a year ago. Basic earnings per share from continuing operations was KRW 903 compared to KRW 459 a year ago. Diluted earnings per share from continuing operations was KRW 903 compared to KRW 459 a year ago. Basic earnings per share was KRW 903 compared to KRW 487 a year ago.
For the nine months, sales was KRW 4,087.66 million compared to KRW 3,703 million a year ago. Net income was KRW 25,639.76 million compared to KRW 14,012.16 million a year ago. Basic earnings per share from continuing operations was KRW 2,093 compared to KRW 1,119 a year ago. Diluted earnings per share from continuing operations was KRW 2,093 compared to KRW 1,119 a year ago. Basic earnings per share was KRW 2,093 compared to KRW 1,139 a year ago.
Huons Global Co., Ltd., formerly, Huons Co., Ltd. is Kore-based entity principally engaged in the manufacture and distribution of pharmaceutical products. Along with its subsidiaries, the Company operates its business through two segments: pharmaceutical segment and glass container segment. The pharmaceutical segment produces pharmaceutical products including parenteral injections such as lidocaines, merit C injections; tablets such as phentermines, diet pills and others; capsules such as Daisen and Fuxetine and other ethical and over-the-counter drugs. The glass container segment produces ampoules, vials, cartridges and caps for used of medicals, foods and cosmetics. The Company also manufactures medical devices such as kits, derma injectors and other injector.
HUONS GLOBAL CO., LTD. 
